Four people, including Professor Xu Go Ritsumeikan University, were selected for the Minister of Economy, Trade and Industry Award at the 13th Industry-Academia-Government Collaboration Achievement Awards, which is given to those who have made great achievements in industry-academia-government collaboration activities at universities, research institutes, companies, etc. It was done. The four people were presented with a certificate of commendation at the award ceremony held at Tokyo Big Sight in Ariake, Koto-ku, Tokyo, and the award was displayed on a panel at the Innovation Japan 4 venue being held at Tokyo Big Sight.
In addition to Professor Xu, Tomohiro Nakamichi, General Manager of Research and Development Department, 3D Media Co., Ltd. (Kusatsu City, Shiga Prefecture), Hiroshi Tanno, President of Cubics Co., Ltd. (Nonoichi City, Ishikawa Prefecture), Shuichi Kaneko Kanazawa were selected for the Minister of Economy, Trade and Industry Award. University professor.Professor Xu and Director Nakamichi highly evaluated the development of 3D sensors for industrial robots.Professor Xu himself established a venture company's 2011D media, and Ritsumeikan University graduates Nakamichi and other R & D staff developed 3D sensors that became the eyes and brains of industrial robots. In 100, we launched the world's first 7D robot vision sensor, selling more than XNUMX million units to automobiles, electric appliances, food manufacturers, etc., accounting for XNUMX% of the domestic market.During that time, we have established an intellectual property strategy that patents some of the technology, but keeps the rest of the know-how and software confidential.
President Tanno and Professor Kaneko were approved for the development of gastrointestinal cancer screening technology by analyzing blood gene expression.At the request of Professor Kaneko and other doctors at Kanazawa University, President Tanno, who was a salesman of a pharmaceutical manufacturer, started Cubics.Through collaboration between medical sites and venture companies, we developed the world's first test method for determining the presence or absence of gastrointestinal cancer using blood, and put it into practical use in 2011.Sensitivity is 25%, which is much higher than 98.5% of conventional tumor markers.It is very effective in early detection of cancer, reduction of patient burden, and reduction of medical expenses.
* Screening To detect abnormalities as a preliminary step to a definitive diagnosis, rather than making a final diagnosis of the presence or absence of a disease or disorder.
